Study Comparing Oral Dydrogesterone Versus Placebo for Luteal Phase Support in Natural Cycle Frozen Embryo Transfer for Women with Subfertility

What this Trial Is About

Researchers are evaluating the live birth rate in women undergoing natural cycle frozen-thawed embryo transfer FET with and without oral dydrogesterone as luteal phase support. This randomized double-blinded controlled trial aims to test the hypothesis that oral dydrogesterone may increase the live birth rate in natural cycle FET. The study is conducted at the Centre of Assisted Reproduction and Embryology, The University of Hong Kong-Queen Mary Hospital. Participants will be randomly assigned to one of two groups one receiving oral dydrogesterone 10mg three times daily and the other receiving a placebo, both starting the day after the luteinizing hormone LH surge or human chorionic gonadotropin hCG induced ovulation, for two weeks. Embryo transfer is performed on the third or sixth day after the LH surge or hCG trigger depending on embryo stage. Women are closely monitored with pelvic ultrasounds and blood tests to track ovulation and hormone levels. During the study, participants will undergo daily monitoring leading up to ovulation and embryo transfer. Pregnancy testing occurs 16 days after FET, and pregnancy outcomes are followed for analysis. Researchers measure live birth rate as the primary outcome and also track clinical pregnancy rate, ongoing pregnancy rate, and pregnancy loss. The study includes detailed monitoring and follow-up over several weeks post-transfer to assess the effects of the treatment.

Oral Dydrogesterone as Luteal Phase Support in Natural Cycle FET